Further Update of Proposed USA Medicare Changes
ASX Announcement General iTrack Molteno3 AlphaRET
28 Nov, 2023
AGM Presentation
ASX Announcement General iTrack Molteno3 AlphaRET
23 Nov, 2023
Further Update on Proposed USA Medicare Changes
ASX Announcement General iTrack Molteno3 AlphaRET
14 Nov, 2023
Trading Halt
ASX Announcement General iTrack Molteno3 AlphaRET
10 Nov, 2023
Proposed USA Medicare Changes
ASX Announcement General iTrack Molteno3 AlphaRET
31 Oct, 2023
Trading Halt
ASX Announcement General iTrack Molteno3 AlphaRET
27 Oct, 2023
Preliminary Clinical Results Shows Potential For Addressable Market
ASX Announcement iTrack
25 Oct, 2023
Notice of Annual General Meeting
ASX Announcement General iTrack Molteno3 AlphaRET
20 Oct, 2023
Date of AGM & Closing Date for Director Nominations
ASX Announcement General iTrack Molteno3 AlphaRET
25 Sept, 2023
INVESTOR WEBINAR PRESENTATION - SHARECAFE
ASX Announcement General iTrack Molteno3 AlphaRET
15 Sept, 2023
Evans & Partners Small Cap Healthcare Conference Presentation
ASX Announcement General iTrack Molteno3 AlphaRET
12 Sept, 2023
EYE FY2023 Results Announcement
ASX Announcement General iTrack Molteno3 AlphaRET
28 Aug, 2023
EYE FY2023 Appendix 4E and Annual Report
ASX Announcement General iTrack Molteno3 AlphaRET
28 Aug, 2023
EYE FY2023 Results Presentation
ASX Announcement General iTrack Molteno3 AlphaRET
28 Aug, 2023
EYE FY2023 Appendix 4G and Governance Statement
ASX Announcement General iTrack Molteno3 AlphaRET
28 Aug, 2023
Investor Webinar Full Year (FY23) Results
ASX Announcement General iTrack Molteno3 AlphaRET
23 Aug, 2023
TechKnow Invest Roadshow Presentation August 2023
ASX Announcement General iTrack Molteno3 AlphaRET
3 Aug, 2023
iTrack™ Advance Sales in the USA Driving Strong Results
ASX Announcement General iTrack Molteno3 AlphaRET
2 Aug, 2023
Investor Presentation - ShareCafe
ASX Announcement General iTrack Molteno3 AlphaRET
19 May, 2023
Cleansing Notice
ASX Announcement General iTrack Molteno3 AlphaRET
5 May, 2023
Application for Quotation of Securities
ASX Announcement General iTrack Molteno3 AlphaRET
5 May, 2023
iTrack Advance First Surgeries and Sales in USA
ASX Announcement General iTrack Molteno3 AlphaRET
1 May, 2023
FDA Clears iTrack Advance for US Launch
ASX Announcement General iTrack Molteno3 AlphaRET
31 Mar, 2023
Notice of General Meeting
ASX Announcement General iTrack Molteno3 AlphaRET
28 Mar, 2023
Application for Quotation of Securities
ASX Announcement General iTrack Molteno3 AlphaRET
8 Mar, 2023
Cleansing Notice
ASX Announcement General iTrack Molteno3 AlphaRET
8 Mar, 2023
Reinstatement to Quotation
ASX Announcement General iTrack Molteno3 AlphaRET
2 Mar, 2023
Proposed issue of securities - 2 March 2023
ASX Announcement General iTrack Molteno3 AlphaRET
2 Mar, 2023
Half Yearly Accounts 31 December 2022
ASX Announcement General iTrack Molteno3 AlphaRET
2 Mar, 2023
Investor Presentation Half Year Results 31 Dec 2022
ASX Announcement General iTrack Molteno3 AlphaRET
2 Mar, 2023
Nova Eye Completes $8m Placement
ASX Announcement General iTrack Molteno3 AlphaRET
2 Mar, 2023
Suspension from Official Quotation
ASX Announcement General iTrack Molteno3 AlphaRET
28 Feb, 2023
Trading Halt
ASX Announcement General iTrack Molteno3 AlphaRET
27 Feb, 2023
Glaucoma Surgical Devices Sales Update
ASX Announcement General iTrack
31 Jan, 2023
Additional Clinical Role for 2RT
ASX Announcement AlphaRET
25 Jan, 2023
Status of Market Clearance for iTrack Advance in the USA
ASX Announcement General iTrack Molteno3 AlphaRET
12 Dec, 2022
AGM Presentation 2022
ASX Announcement General iTrack Molteno3 AlphaRET
17 Nov, 2022
Glaucoma Surgical Devices Sales Update
ASX Announcement General iTrack Molteno3 AlphaRET
16 Nov, 2022
AlphaRET Completes Initial Recruitment of Investigator Sites for 2RT® Confirmatory Pivotal Study
ASX Announcement General iTrack AlphaRET
24 Oct, 2022
Notice of Annual General Meeting
ASX Announcement General iTrack Molteno3 AlphaRET
14 Oct, 2022
2RT Presentation Professor Robyn H Guymer Today 15 Sept 2022
ASX Announcement General AlphaRET
15 Sept, 2022
AGM Date and Directors Nominations
ASX Announcement General iTrack Molteno3 AlphaRET
14 Sept, 2022
EYE 2RT Webinar Prof Guymer
ASX Announcement General iTrack Molteno3 AlphaRET
9 Sept, 2022
EYE FY22 Appendix 4G & Governance Statement
ASX Announcement General iTrack Molteno3 AlphaRET
26 Aug, 2022
EYE FY22 Results Presentation
ASX Announcement General iTrack Molteno3 AlphaRET
26 Aug, 2022
EYE FY22 Results Announcement
ASX Announcement General iTrack Molteno3 AlphaRET
26 Aug, 2022
EYE FY22 Appendix 4E & Annual Report
ASX Announcement General iTrack Molteno3 AlphaRET
26 Aug, 2022
Sales Performance Glaucoma Surgical Devices Segment
ASX Announcement General iTrack Molteno3
8 July, 2022
Nova Eye Medical Launches iTrack Advance
ASX Announcement General iTrack Molteno3 AlphaRET
8 June, 2022
2RT Pivotal Study and Regulatory Pathway Presentation
ASX Announcement General AlphaRET
3 May, 2022
Nova Eye Medical Announces Regulatory Pathway for AlphaRET 2RT in the USA
ASX Announcement General AlphaRET
3 May, 2022
EYE Appointment to AGS Board
ASX Announcement iTrack
31 Mar, 2022
Investor Presentation Half Year Results 31 December 2021
ASX Announcement General iTrack Molteno3 AlphaRET
17 Feb, 2022
Global Revenue of A$6.5m for 6 Months Ended 31 Dec 2021
ASX Announcement General iTrack Molteno3 AlphaRET
17 Feb, 2022
Half Yearly Report and Accounts
ASX Announcement General iTrack Molteno3 AlphaRET
17 Feb, 2022
Glaucoma Sales Update for 6 Months Ended 31 Dec 2021
ASX Announcement General iTrack
1 Feb, 2022
Presentation - Reducing Progression Rate of Age-Related Macular Degeneration
ASX Announcement General AlphaRET
21 Dec, 2021
For investor enquires please contact:
Mark Flynn
Nova Eye Medical Limited
W +61 416 068 733
mflynn@nova-eye.com
This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More
The cookies do not store any personalised information. Learn More